Clinical findings of hyperechoic substantia nigra in patients with Parkinson's disease

被引:1
作者
Fan, Yongyan [1 ,2 ]
Ma, Jianjun [1 ,2 ,3 ,4 ]
Yang, Dawei [1 ,2 ]
Li, Xiaohuan [1 ,2 ]
Liang, Keke [2 ,3 ]
She, Zonghan [1 ,2 ]
Qi, Xuelin [1 ,2 ]
Shi, Xiaoxue [1 ,2 ,3 ]
Gu, Qi [1 ,2 ,3 ]
Zheng, Jinhua [1 ,2 ,3 ]
Li, Dongsheng [1 ,2 ,3 ]
机构
[1] Zhengzhou Univ, Peoples Hosp, Dept Neurol, Zhengzhou, Peoples R China
[2] Henan Prov Peoples Hosp, Dept Neurol, Zhengzhou, Peoples R China
[3] Henan Univ, Peoples Hosp, Dept Neurol, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Peoples Hosp, Dept Neurol, Zhengzhou 450003, Peoples R China
关键词
biomarker; hyperechoic substantia nigra; iron deposition; microglial activation; Parkinson's disease; TRANSCRANIAL BRAIN SONOGRAPHY; IRON ACCUMULATION; URIC-ACID; DIFFERENTIAL-DIAGNOSIS; TASK-FORCE; HYPERECHOGENICITY; ECHOGENICITY; SENSITIVITY; SCALE; REPRODUCIBILITY;
D O I
10.1111/ejn.16308
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This study aims to analyse hyperechoic substantia nigra (HSN) characteristics and the correlation of HSN with clinical features and blood biomarkers in patients with Parkinson's disease (PD). Transcranial sonography (TCS) evaluations of the substantia nigra (SN) were performed in 40 healthy controls and 71 patients with PD, including patients with SN hyperechogenicity (SN+) and those with normal SN echogenicity (SN-). Evaluation of motor and non-motor symptoms was assessed by a series of rating scales. The uricase method was used to determine serum uric acid (UA) levels, and enzyme-linked immunosorbent assay (ELISA) was used to measure plasma interleukin (IL)-1 beta levels. TCS showed 92.50% specificity and 61.97% sensitivity in differentiating PD patients from controls. The area of SN+ contralateral to the side of initial motor symptoms (SNcontra) was larger than that ipsilateral to the side of initial motor symptoms (SNipsi). The PDSN+ group had lower Argentine Hyposmia Rating Scale (AHRS) scores and UA levels than the PDSN- group. Binary logistic regression analysis revealed that AHRS scores and UA levels could be independent predictors for HSN. The larger SN echogenic area (SNL) sizes positively correlated with plasma IL-1 beta levels in PD patients with SN+. The present study provides further evidence of the potential of SN echogenicity as an imaging biomarker for PD diagnosis. PD patients with HSN have more severe non-motor symptoms of hyposmia. HSN in PD patients is related to the mechanism of abnormal iron metabolism and microglial activation. Transcranial sonography (TCS) has potential as a tool for Parkinson's disease (PD) diagnosis. Hyperechoic substantia nigra (HSN) is a stable marker during the course of PD and does not reflect disease progression. PD patients with HSN have severer non-motor symptoms of hyposmia. HSN in PD patients is related to the mechanism of abnormal iron metabolism and microglial activation. image
引用
收藏
页码:2702 / 2714
页数:13
相关论文
共 50 条
  • [21] The role of substantia nigra sonography in the differentiation of Parkinson's disease and multiple system atrophy
    Zhou, Hai-Yan
    Huang, Pei
    Sun, Qian
    Du, Juan-Juan
    Cui, Shi-Shuang
    Hu, Yun-Yun
    Zhan, Wei-Wei
    Wang, Ying
    Xiao, Qin
    Liu, Jun
    Tan, Yu-Yan
    Chen, Sheng-Di
    TRANSLATIONAL NEURODEGENERATION, 2018, 7
  • [22] Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes
    Berg, Daniela
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (04) : 613 - 619
  • [23] No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease
    Lobsien, Elmar
    Schreiner, Simon
    Plotkin, Michail
    Kupsch, Andreas
    Schreiber, Stephan J.
    Doepp, Florian
    MOVEMENT DISORDERS, 2012, 27 (03) : 450 - 453
  • [24] Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease
    Berg, Daniela
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (03) : 453 - 461
  • [25] Metal dyshomeostasis in the substantia nigra of patients with Parkinson's disease or multiple sclerosis
    Carmona, Asuncion
    Carboni, Eleonora
    Gomes, Lucas Caldi
    Roudeau, Stephane
    Maass, Fabian
    Lenz, Christof
    Ortega, Richard
    Lingor, Paul
    JOURNAL OF NEUROCHEMISTRY, 2024, 168 (02) : 128 - 141
  • [26] Diffusion Tensor Imaging of the Substantia Nigra in Parkinson's Disease Revisited
    Langley, Jason
    Huddleston, Daniel E.
    Merritt, Michael
    Chen, Xiangchuan
    McMurray, Rebecca
    Silver, Michael
    Factor, Stewart A.
    Hu, Xiaoping
    HUMAN BRAIN MAPPING, 2016, 37 (07) : 2547 - 2556
  • [27] Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor
    Sprenger, Fabienne S.
    Wurster, Isabel
    Seppi, Klaus
    Stockner, Heike
    Scherfler, Christoph
    Sojer, Martin
    Schmidauer, Christof
    Berg, Daniela
    Poewe, Werner
    MOVEMENT DISORDERS, 2016, 31 (04) : 579 - 583
  • [28] Transcranial Sonographic Alterations of Substantia Nigra and Third Ventricle in Parkinson's Disease with or without Dementia
    Dong, Zhi-Fen
    Wang, Cai-Shan
    Zhang, Ying-Chun
    Zhang, Ying
    Sheng, Yu-Jing
    Hu, Hua
    Luo, Wei-Feng
    Liu, Chun-Feng
    CHINESE MEDICAL JOURNAL, 2017, 130 (19) : 2291 - 2295
  • [29] Proteasomal function is impaired in substantia nigra in Parkinson's disease
    McNaught, KSP
    Jenner, P
    NEUROSCIENCE LETTERS, 2001, 297 (03) : 191 - 194
  • [30] Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease
    R. K. B. Pearce
    A. Owen
    S. Daniel
    P. Jenner
    C. D. Marsden
    Journal of Neural Transmission, 1997, 104 : 661 - 677